Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells

Cancer Genomics and Proteomics

Volumn 5, Issue 5, 2008, Pages 275-286

  Schuster, Friedhelm R ^a   Buhmann, Raymund ^b   Reuther, Susanne ^a   Hubner, Bernd ^a   Grabrucker, Christine ^b   Liepert, Anja ^b   Reibke, Roland ^b   Lichtner, Peter ^b   Yang, Ting ^b   Kroell, Tanja ^b   Kolb, Hans Jochem ^b   Borkhardt, Arndt ^a   Schmetzer, Helga ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

AML; DC; Immunotherapy; Spectratyping; Stem cell transplantation; T cells

Indexed keywords

CD45RO ANTIGEN; HLA ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANALYTICAL EQUIPMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL ASSAY; CELL CLONING; CELL FRACTIONATION; CELL FUNCTION; CELL SPECIFICITY; CELL STIMULATION; DENDRITIC CELL; EFFECTOR CELL; FLOW CYTOMETRY; IMMUNOSCOPE SPECTRATYPING; LEUKEMIA CELL; MEMORY T LYMPHOCYTE; T LYMPHOCYTE;

EID: 57249091723     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Giles FJ, Keating A, Goldstone AH et al: Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program, pp. 73-110, 2002.
2. Buchner T, Hiddemann W, Berdel WE et al: 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 21(24): 4496-4504, 2003.
3. Kolb HJ, Schmid C, Barrett AJ and Schendel DJ: Graft-versus- leukemia reactions in allogeneic chimeras. Blood 103(3): 767-776, 2004.
4. Kolb HJ, Schattenberg A, Goldman JM et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86(5): 2041-2050, 1995.
5. Schmid C, Schleuning M, Schwerdtfeger R et al: Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3): 1092-1099, 2006.
6. Restifo NP, Minev BR, Taggarse AS et al: Enhancing the recognition of tumour associated antigens. Folia Biol (Praha) 40(1-2): 74-88, 1994.
7. Brossart P: Dendritic cells in vaccination therapies of malignant diseases. Transfus Apher Sci 27(2): 183-186, 2002.
8. Cella M, Sallusto F and Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9(1): 10-16, 1997.
9. Nestle FO, Banchereau J and Hart D: Dendritic cells: On the move from bench to bedside. Nat Med 7(7): 761-765, 2001.
10. Claxton DF, McMannis J, Champlin R and Choudhury A: Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress. Crit Rev Immunol 21(1-3): 147-155, 2001.
11. Stripecke R, Levine AM, Pullarkat V and Cardoso AA: Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 16(10): 1974-1983, 2002.
12. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 90(4): 1458-1470, 1997.
13. Choudhury BA, Liang JC, Thomas EK et al: Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93(3): 780-786, 1999.
14. Lee AW, Truong T, Bickham K et al: A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl 4): A8-A22, 2002.
15. Houtenbos I, Westers TM, Stam AG et al: Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer Immunol Immunother 52(7): 455-462, 2003.
16. Sato M, Takayama T, Tanaka H et al: Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2). Cancer Sci 94(12): 1091-1098, 2003.
17. Loibl J, Kremser S, Kufner T et al: Expression profiles of leukemia-derived dendritic cells in AML and MDS depending on different culture conditions. Submitted for publication 2008.
18. Schmetzer H, Liepert A, Grabrucker C et al: Role of the quality and quantity of leukemia-derived dedritic cells and anti-leukemia-directed T-cells to predict the course and success of immunotherapy. Bone Marrow Transplantation 39(1): 0302, 2007.
19. Janeway C, Murphy K, Travers P and Walport M: Immunobiology. New York, Garland Science, Taylor & Francis Group, LLC, pp. 155-159, 2008.
20. Gorski J, Yassai M, Zhu X et al: Circulating T-cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 152(10): 5109-5119, 1994.
21. Babbe H, Roers A, Waisman A et al: Clonal expansions of CD8(+) T-cells dominate the T-cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192(3): 393-404, 2000.
22. Michalek J, Collins RH, Hill BJ et al: Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet 361(9364): 1183-1185, 2003.
23. Bennett JM, Catovsky D, Daniel MT et al: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4): 451-458, 1976.
24. Mitelman F: Guidelines for Cancer Cytogenetics. Basel, Switzerland S. Karger, 1995 ISCN 1995.
25. Schmetzer HM, Kremser A, Loibl J et al: Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia 21(6): 1338-1341, 2007.
26. high regulatory cells in human peripheral blood. J Inummol 167(3): 1245-1253, 2001.
27. Campana D and Behin. FG: Immunophenotyping of leukemia. J Immunol Methods 243(1-2): 59-75, 2000.
28. Kufner S, Fleischer RP, Kroell T et al: Serum-free generation and quantification of functionally active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother 54(10): 953-970, 2005.
29. Lanzavecchia A and Sallusto F: Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2(12): 982-987, 2002.
30. Nguyen XD, Eichler H, Dugrillon A et al: Flow cytometric analysis of T-cell proliferation in a mixed lymphocyte reaction with dendritic cells. J Inummol Methods 275(1-2): 57-68, 2003.
31. Kienzle N, Olver S, Buttigieg K and Kelso A: The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T-cells at very low numbers. J Immunol Methods 267(2): 99-108, 2002.
32. + T-cells in multiple sclerosis. Autoimmunity 23(2): 127-138, 1996.
33. Puisieux I, Even J, Pannetier C et al: Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 153(6): 2807-2818, 1994.
34. Lu J, Basu A, Melenhorst JJ et al: Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood 103(12): 4588-4593, 2004.
35. Childs R and Barrett J: Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. Semin Hematol 39(1): 63-71, 2002.
36. Childs R, Chernoff A, Contentin N et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11): 750-758, 2000.
37. Giralt S, Hester J, Huh Y et al: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86(11): 4337-4343, 1995.
38. + donor T-cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 8(7): 2052-2060, 2002.
39. Wotton D, Ways DK, Parker PJ and Owen MJ: Activity of both Raf and Ras is necessary for activation of transcription of the human T-cell receptor beta gene by protein kinase C, Ras plays multiple roles. J Biol Chem 268(24): 17975-17982, 1993.
40. Schmetzer HM and Gerhartz HH: Acute myeloid leukemia (AML) can be oligoclonal. Leukemia 7(12): 1965-1970, 1993.